{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T04:09:35Z","timestamp":1750133375122,"version":"3.41.0"},"reference-count":15,"publisher":"Korean Ophthalmological Society","issue":"3","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ekjo.org"],"crossmark-restriction":true},"short-container-title":["Korean J Ophthalmol"],"published-print":{"date-parts":[[2025,6,5]]},"abstract":"<jats:p>Purpose: To investigate the outcomes of brolucizumab reinjection after intraocular inflammation (IOI) development.Methods: This retrospective study analyzed patients with brolucizumab injections from April 2021 to January 2024. Patients who developed IOI after brolucizumab were included and categorized into subgroups depending on reinjection, discontinuation, and further IOI development.Results: A total of 472 eyes of 432 patients received brolucizumab injections. Thirty-eight cases developed IOI at least once, and 25 continued brolucizumab. Sixteen cases had no more IOI events, and nine experienced a second or more IOI events. Among the nine cases, three maintained brolucizumab injections despite IOI recurrence. The incidence of IOI was 8.1% based on the number of eyes (38 of 472 eyes) and 2.0% based on the number of brolucizumab injections (50 of 2,468 injections). The incidence of occlusive retinal vasculitis was 0.2% (1 of 472 eyes). The recurrence rate was 23.7% (9 of 38 eyes). The average number of injections between the first brolucizumab injection and the injection date on which IOI first developed was 2.15 times in the no-reinjection group, 3.44 times in the no-IOI-recurrence group, and 2.0 times in the second-IOI-episode group. Time to IOI occurrence in cases with first IOI episode was 18.60 \u00b1 16.73 days, with 15 cases developing IOI within 1 week.Conclusions: This study elucidates the real-world incidence of brolucizumab associated IOIs, with a description of information related to reinjections after the IOI episodes. A comprehensive understanding of brolucizumab reinjection is essential for its optimal utilization.<\/jats:p>","DOI":"10.3341\/kjo.2024.0125","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:15:41Z","timestamp":1744780541000},"page":"213-221","update-policy":"https:\/\/doi.org\/10.3341\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reinjection in Patients with Intraocular Inflammation Development after Intravitreal Brolucizumab Injection"],"prefix":"10.3341","volume":"39","author":[{"given":"Myung Ae","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Il","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Sub","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Sung","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Ki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oh Woong","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1893","reference":[{"volume-title":"","year":"2004","key":"ref1"},{"key":"ref2","first-page":"A17","volume-title":"Age-related eye diseases: an emerging challenge for public health professionals","author":"Gohdes","year":"2005"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27165089"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000526703"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.2-a.s3"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01713-3"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01231-9"},{"key":"ref8","first-page":"1323","volume-title":"Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration","author":"Yannuzzi","year":"2019"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"ref10","first-page":"89","volume-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","author":"Dugel","year":"2021"},{"key":"ref11","first-page":"1050","volume-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","author":"Mones","year":"2021"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2021.05.003"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.06.009"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420975303"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0981"}],"container-title":["Korean Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ekjo.org\/upload\/pdf\/kjo-2024-0125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ekjo.org\/journal\/view.php?doi=10.3341\/kjo.2024.0125","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ekjo.org\/upload\/pdf\/kjo-2024-0125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T02:13:00Z","timestamp":1750126380000},"score":1,"resource":{"primary":{"URL":"http:\/\/ekjo.org\/journal\/view.php?doi=10.3341\/kjo.2024.0125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.3341\/kjo.2024.0125","relation":{},"ISSN":["1011-8942","2092-9382"],"issn-type":[{"type":"print","value":"1011-8942"},{"type":"electronic","value":"2092-9382"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"2024-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-16","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-05","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}